A share price of Akero Therapeutics Inc [AKRO] is currently trading at $44.15, down -1.58%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AKRO shares have gain 4.82% over the last week, with a monthly amount drifted -10.70%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Akero Therapeutics Inc [NASDAQ: AKRO] stock has seen the most recent analyst activity on January 30, 2025, when BofA Securities upgraded its rating to a Buy and also boosted its price target to $63 from $35. Previously, H.C. Wainwright reaffirmed its Buy rating on January 27, 2025, and elevated its price target to $72. On November 18, 2024, Citigroup initiated with a Buy rating and assigned a price target of $65 on the stock. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $69 as its price target on September 19, 2023. UBS started tracking with a Buy rating for this stock on August 28, 2023, and assigned it a price target of $83. In a note dated January 27, 2023, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $40 to $65.
Akero Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $17.86 and $58.40. Currently, Wall Street analysts expect the stock to reach $50 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $44.15 at the most recent close of the market. An investor can expect a potential return of 13.25% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.32 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 43.56 points at the first support level, and at 42.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 45.16, and for the 2nd resistance point, it is at 46.17.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Akero Therapeutics Inc [NASDAQ:AKRO] is 19.38. In addition, the Quick Ratio stands at 19.38 and the Cash Ratio stands at 8.56.
Transactions by insiders
Recent insider trading involved Cheng Andrew, President and CEO, that happened on Mar 12 ’25 when 1738.0 shares were sold. Chief Operating Officer, Young Jonathan completed a deal on Mar 12 ’25 to sell 607.0 shares. Meanwhile, Chief Development Officer Yale Catriona sold 614.0 shares on Mar 12 ’25.
